- ►annals.org R de Franchis, G Meucci, M Vecchi, M … - Annals of internal …, 1993 - Am Coll Physicians Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg Add to Facebook
Add to Reddit Add to Technorati Add to Twitter What's this? ... Objective: To assess the
long-term outcome in hepatitis B surface antigen (HBsAg) carriers who have normal liver ... Cited by 201 - Related articles - All 3 versions
JP Villeneuve, M Desrochers, C Infante-Rivard, B … - Gastroenterology, 1994 - ncbi.nlm.nih.gov BACKGROUND/AIMS: Prospective studies from the Far East and Alaska have shown an increased
mortality from cirrhosis and/or hepatocellular carcinoma in asymptomatic hepatitis B virus
(HBV) carriers. The magnitude of this risk in apparently healthy North American carriers ... Cited by 124 - Related articles - BL Direct - All 6 versions
YS Hsu, RN Chien, CT Yeh, IS Sheen, HY Chiou, … - Hepatology, 2002 - interscience.wiley.com During the course of chronic hepatitis B virus (HBV) infection, hepatitis B e antigen (HBeAg) seroconversion
to its antibody (anti-HBe) often coincides with normalization of liver biochemical test and clinical
remission, but data regarding long-term outcome after spontaneous seroconversion are ... Cited by 296 - Related articles - BL Direct - All 4 versions
G Fattovich, G Giustina, J Sanchez-Tapias … - … American journal of …, 1998 - interscience.wiley.com *Additional members of the European Concerted Action on Viral Hepatitis (EUROHEP) participating
in this study were: Craxì A, Istituto di Clinica Medica I, University of Palermo, Palermo, Italy; Delarocque
E, Fédération d'Hépatogastroentérologie et INSERM U24, Hôpital Beaujon, Paris, France; ... Cited by 98 - Related articles - BL Direct - All 5 versions
BJ McMahon, P Holck, L Bulkow, M … - Annals of internal …, 2001 - Am Coll Physicians Objective: To determine the incidence of and risk factors for adverse events (hepatocellular carcinoma
and end-stage liver disease) and clearance of hepatitis B e antigen (HBeAg) and surface antigen
(HBsAg) in carriers of HBV. ... Design: Population-based cohort study of hepatitis B ... Cited by 203 - Related articles - All 9 versions
FE De Jongh, HL Janssen, RA De Man, WC Hop, … - Gastroenterology, 1992 - ncbi.nlm.nih.gov To evaluate indications for new therapies such as liver transplantation and antiviral therapy,
survival of histologically proven hepatitis B surface antigen (HBsAg)-positive cirrhosis of the liver
was assessed in a cohort of 98 patients followed up for a mean of 4.3 years. The overall ... Cited by 309 - Related articles - BL Direct - All 4 versions
- ►nih.gov [PDF] G Fattovich, L Brollo, G Giustina, F Noventa, P … - British Medical …, 1991 - gut.bmj.com Abstract One hundred and five hepatitis B surface antigen (HBsAg) positive patients presenting
with chronic persistent hepatitis (n=46) or chronic active hepatitis without cirrhosis (n=59) were
followed longitudinally for one to 16 years (mean 5.5 years) and underwent follow up ... Cited by 325 - Related articles - All 7 versions
B Dragosics, P Ferenci, E Hitchman, H Denk - Hepatology, 1987 - interscience.wiley.com Two hundred forty-two voluntary blood donors, referred after detection of HBsAg positivity, underwent
clinical evaluation and liver biopsy and were prospectively followed for an average of 3.5
years. At initial testing, 65% of HBsAg carriers had normal laboratory findings; during ... Cited by 81 - Related articles - All 3 versions
M Manno, C Cammà, F Schepis, F Bassi, R Gelmini, F … - Gastroenterology, 2004 - Elsevier Background & aims: Increased morbidity and mortality from liver disease have been reported
in chronic hepatitis B surface antigen (HBsAg) carriers, but data on survival are equivocal. To
assess the impact of hepatitis B virus (HBV) infection on survival and liver-related ... Cited by 99 - Related articles - BL Direct - All 11 versions
YF Liaw, DI Tai, CM Chu, TJ Chen - Hepatology, 1988 - interscience.wiley.com The incidence and contributing factors of cirrhosis developing in patients with chronic type B
hepatitis were assessed prospectively in 684 clinicopathologically verified patients, of which
509 were HBeAg positive and 175 were anti-HBe positive at entry into the study. During ... Cited by 414 - Related articles - All 4 versions
